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Abstract
Background: Prostaglandin (PG) F2a is a key regulator of endometrial function and exerts its biological action after
coupling with its heptahelical G protein-coupled receptor (FP receptor). In endometrial adenocarcinoma the FP
receptor expression is elevated. We have shown previously that PGF2a-FP receptor signalling in endometrial
adenocarcinoma cells can upregulate several angiogenic factors including fibroblast growth factor-2 (FGF2). In the
present study, we investigated the paracrine effect of conditioned medium produced via PGF2a-FP receptor
signalling in endometrial adenocarcinoma cells stably expressing the FP receptor (Ishikawa FPS cells), on
endothelial cell function.
Results: Conditioned medium (CM) was collected from FPS cells after 24 hrs treatment with either vehicle (V CM)
or 100 nM PGF2a (P CM). Treatment of human umbilical vein endothelial cells (HUVECs) with P CM significantly
enhanced endothelial cell differentiation (network formation) and proliferation. Using chemical inhibitors of
intracellular signalling, we found that P CM-stimulated endothelial cell network formation was mediated by
secretion of endothelial PGF2a and activation of endothelial FP receptors, following FGF2-FGFR1 signalling,
phosphorylation of ERK1/2 and induction of COX-2. Whereas, P CM stimulation of endothelial cell proliferation
occurred independently of PGF2a secretion via an FGF2-FGFR1-ERK1/2 dependent mechanism involving activation
of the mTOR pathway.
Conclusions: Taken together, we have shown a novel mechanism whereby epithelial prostaglandin F2a-FP
signalling regulates endothelial cell network formation and proliferation. In addition we provide novel in vitro
evidence to suggest that prostaglandin F2a can directly regulate endothelial cell network formation but not
endothelial cell proliferation. These findings have relevance for pathologies where the FP receptor is aberrantly
expressed, such as endometrial adenocarcinoma, and provide in vitro evidence to suggest that targeting the FP
receptor could provide an anti-angiogenic approach to reducing tumour vasculature and growth.
Background
Endometrial adenocarcinoma, originating from the
glandular epithelial cells of the uterine endometrial lin-
ing, is one of the most prevalent cancers amongst
women in the Western world [1,2]. It is a disease which
particularly occurs in post menopausal women and
recent evidence suggests that mutations in oncogene
expression may play a role in the etiology of the disease
[3]. Data generated in our laboratory and others have
ascertained a role for the cyclooxygenase (COX)-prosta-
glandin (PG) axis in the regulation of endometrial ade-
nocarcinomas by increasing cell proliferation and the
secretion of angiogenic growth factors [4,5]. This is
similar to other cancers where over-expression of COX
enzymes and biosynthesis of prostaglandins has been
shown to promote cellular proliferation [6], inhibit
apoptosis [7] and enhance angiogenesis [8]. However,
the molecular mechanisms mediating the role of prosta-
glandins in regulating vascular function and angiogen-
esis are still poorly defined.
Angiogenesis is the process of endothelial cell sprout-
ing from an existing vasculature towards cancer cells [9]
and is required by any tumour larger than 2 mm in dia-
meter [10]. The proposed mechanism of angiogenesis
suggests that tumour cells secrete stimulatory factors
which act in a paracrine manner on surrounding blood
vessels, immune cells and fibroblasts to promote the
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cells towards the stimulus [10,11]. These tumour stimu-
latory factors include vascular endothelial growth factor
(VEGF-A) and fibroblast growth factor 2 (FGF2). In
human endometrial adenocarcinomas VEGF-A and
FGF2 expression and secretion are elevated [12-14] and
both VEGF-A and FGF2 can stimulate angiogenesis in
xenografts in vivo [15,16].
In a previous study we demonstrated elevated expres-
sion of the FP receptor, FGF2 and the FGF2 receptor 1
(FGFR1) in neoplastic endometrial epithelial and vascu-
lar cells and ascertained a role for the FGF2, produced
by PGF2a-FP receptor signalling, on epithelial cell prolif-
eration [12]. In this study we have shown that condi-
tioned medium from PGF2a treated Ishikawa cells stably
expressing the FP receptor (Ishikawa FPS cells), can
increase endothelial cell differentiation (network forma-
tion) and proliferation. Treatment of Ishikawa FPS cells
with PGF2a increases FGF2 secretion which in turn acti-
vates FGFR1 signalling in endothelial cells and induces
the phosphorylation of extracellular signal-regulated
kinase (ERK1/2), COX-2 expression and secretion of
PGF2a. Following its release from endothelial cells, we
show for the first time that, PGF2a promotes endothelial
cell network formation in an autocrine/paracrine man-
ner, via the endothelial FP receptor. By contrast, PGF2a
is not involved in endothelial cell proliferation which we
show to be regulated by FGF2-FGFR1 signalling via the
mammalian target of rapamycin (mTOR) pathway.
Taken together, our data highlight two molecular path-
ways by which PGF2a-FP receptor signalling can regu-
late endothelial cell function in endometrial
adenocarcinomas.
Results
PGF2a-FP signalling mediates endothelial cell network
formation and proliferation via FGF2-FGFR1 signalling
We previously demonstrated elevated expression of the
FP receptor, FGF2 and FGFR1 in endometrial adenocar-
cinoma [12]. Using a neoplastic epithelial cell line stably
expressing the FP receptor to the levels observed in
endometrial adenocarcinoma (Ishikawa FPS cells), we
ascertained a role for FGF2, produced by PGF2a-FP
receptor signalling, on epithelial cell proliferation [12].
In addition, we found that FP receptor, FGF2 and
FGFR1 co-localised within the vascular endothelial cells
in endometrial adenocarcinomas suggesting that PGF2a
may directly and indirectly regulate endothelial cell
function [12]. To determine if the effects of PGF2a-FP
receptor interaction in endometrial adenocarcinoma
cells on endothelial cell function were mediated by
FGF2, we used conditioned medium (CM) from Ishi-
kawa FPS cells treated with vehicle or 100 nM PGF2a
for 24 hours. The presence of FGF2 in CM from vehicle
(V CM) and PGF2a-treated (P CM) Ishikawa FPS cells
was confirmed by ELISA. Immunoneutralisation of P
CM with FGF2 antibody significantly reduced FGF2
concentration in P CM [12].
To assess the effects of the CM on differentiation
(network formation) and proliferation, assays were per-
formed using HUVECs as a model system. Treatment of
HUVECs with P CM significantly increased endothelial
cell network formation (Fig. 1A and 1B, P < 0.05) and
proliferation (Fig. 1C, P < 0.05) compared to V CM-
treated cells. Treatment of HUVECs with P CM in the
presence of the FGF2 receptor 1 (FGFR1) tyrosine
kinase inhibitor (SU4984) or FGF2-immunoneutralised
CM (FGF2-Ab), significantly reduced endothelial cell
network formation (Fig. 1A and 1B; P < 0.05) and cellu-
lar proliferation (Fig. 1C; P < 0.05), confirming that
these alterations in endothelial cell function were
mediated by FGF2 in the P CM signalling through
endothelial FGFR1.
Next we investigated the signal transduction pathways
mediating the role of FGF2 in the P CM on network
formation and proliferation. HUVECs were treated with
P CM in the presence of cell signalling inhibitors of
extracellular signal-regulated kinase (ERK1/2; PD98059),
mammalian target of rapamycin (mTOR; rapamycin) or
phosphoinositide-3-kinase (PI3K; wortmannin or
LY294002). We found that the P CM-induced network
formation was significantly inhibited by PD98059 but
not rapamycin, wortmannin or LY294002 (Fig. 2A, P <
0.05). However, endothelial cell proliferation was inhib-
ited by PD98059 and rapamycin but not wortmannin or
LY294002 (Fig. 2B, P < 0.05).
We confirmed that endothelial cell proliferation but
not network formation was mediated by FGF2-mTOR
signalling using recombinant FGF2 protein. Treatment
of HUVECs with recombinant FGF2 significantly
increased network formation (Fig. 2C; P < 0.05) and
proliferation (Fig. 2D; P < 0.05). Co-treatment of cells
with recombinant FGF2 protein and rapamycin had no
effect on network formation, compared to recombinant
FGF2 peptide alone (Fig. 2C; P < 0.05). In contrast,
rapamycin treatment significantly inhibited endothelial
cell proliferation induced by the recombinant FGF2 pro-
tein (Fig. 2D; P < 0.05) confirming that endothelial cell
proliferation was mediated by P CM via the FGF-
FGFR1-mediated induction of the mTOR pathway.
ERK1/2 phosphorylation is regulated by FGF2- FGFR1
signalling
As ERK1/2 was involved in regulating both P CM
induced endothelial cell network formation and prolif-
eration, we investigated the effect of P CM on ERK1/2
phosphorylation. HUVECs were treated with V CM or P
CM for 0, 5, 10, 15, 20 and 30 mins (Fig. 3A). Treat-
ment of HUVECs with P CM significantly increased
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which was maximal after 10 mins of stimulation, com-
pared to V CM (Fig. 3A; P < 0.05). Co-incubation of
HUVECs with P CM in the presence of FGFR1 tyrosine
kinase inhibitor (SU4984), c-Src inhibitor (PP2) or
ERK1/2 inhibitor (PD98059) significantly reduced the P
CM-stimulated phosphorylation of ERK1/2 to basal
levels (Fig 3B, P < 0.05). However treatment of HUVECs
with P CM in the presence of the PI3K inhibitor
LY294002 did not significantly reduce the P CM phos-
phorylation of ERK1/2 (Fig. 3B). Similarly, co-incubation
of HUVECs with P CM and the mTOR inhibitor, rapa-
mycin, had no effect on ERK1/2 phosphorylation (data
not shown). Treatment of HUVECs with recombinant
FGF2 protein phosphorylated ERK1/2 to the levels
observed with P CM (Fig. 3B).
Conditioned medium from Ishikawa FPS cell treated with
PGF2a induces endothelial COX-2
FGF2 has been shown to mediate angiogenesis via COX-
2 in an in vivo model using rat sponge implants [17],
hence we investigated the effect of P CM on the expres-
sion of COX-1 and COX-2 in endothelial cells. HUVECs
were treated with V CM or P CM for 1, 2, 3, 4, 6, 16
and 24 hrs. We did not observe an alteration in the
expression of COX-1 (Fig. 4A) at any of the time points
investigated in response to P CM stimulation. However,
we observed a significant increase in endothelial COX-2
expression at 3 hours following treatment with P CM
(Fig. 4B; P < 0.05). This increase in COX-2 expression
was inhibited by treatment with P CM in the presence
of the FGFR1 inhibitor, SU4984 or ERK1/2 inhibitor,
PD98059 (Fig. 4C; P < 0.05) indicating that COX-2
expression was regulated via the FGF-2-FGFR1-ERK1/2
signalling pathway.
Cyclooxygenase enzymes are responsible for the cata-
lysis of arachidonic acid to prostaglandins (PG). We
next investigated the secretion of endothelial PGE2 and
PGF2a in response to CM treatment. HUVECs were
treated with V CM or P CM for 0, 3, 6, and 16 hrs and
the secretion of PGE2 (Fig. 4D) and PGF2a (Fig. 4E) was
measured by ELISA. There was no significant difference
in the levels of endothelial PGE2 secreted by HUVECs
in response to CM at any time point tested (Fig. 4D). In
contrast, the amount of endothelial PGF2a was elevated
Figure 1 The effect of PGF2a conditioned medium on endothelial network formation and proliferation. (A) Representative image from
one network formation assay in which HUVECs, plated on growth factor reduced matrigel, were incubated with V CM, P CM or P CM and
SU4984 or FGF2 immunoneutralised CM (FGF2-Ab) for 16 hrs as described in the Methods. (B) Quantification of endothelial network formation
and (C) proliferation using HUVECs stimulated with V CM, P CM or P CM in the presence of FGFR1 tyrosine kinase inhibitor (P CM + SU4984) or
FGF2 immunoneutralised CM (P CM + FGF2Ab). Data are expressed as percentage increase over control V CM (where V CM = 100%, not shown)
and presented as mean ± SEM. (* represents statistical significance P < 0.05).
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pared to both V CM treatment (6 hrs) and P CM at
time 0 hrs (Fig. 4E; P < 0.05). To confirm the involve-
ment of COX in the secretion of PGF2a, we treated
HUVECs for 6 hrs with P CM in the presence of the
specific COX-2 inhibitor NS398 or the general COX
inhibitor indomethacin. We found that the P CM-
induced secretion of PGF2a was significantly reduced by
co-treatment of cells with NS398 (Fig. 4F; P < 0.05).
Similarly, co-treatment of cells with indomethacin sig-
nificantly reduced P CM-induced PGF2a secretion below
the levels observed with P CM alone and P CM with
NS398 (Fig. 4F; P < 0.05).
The role of endothelial prostaglandin F2a-FP signalling in
the regulation of endothelial cell network formation
Since the secretion of PGF2a was elevated in HUVECs
following P CM treatment, we investigated the role of
the F-prostaglandin receptor (FP) in endothelial cell
function. We found a significant elevation in endothelial
FP receptor expression after 3 hrs of treatment with P
CM (Fig. 5A; P < 0.05). To determine if the regulation
of FP receptor was mediated by FGF2 in the P CM, we
co-incubated HUVECs with P CM in the absence/pre-
sence of inhibitors of FGFR1 tyrosine kinase activity
(SU4984) or ERK1/2 (PD98059). Incubation of HUVECs
with P CM and SU4984 or PD98059 significantly
Figure 2 Endothelial network formation and proliferation is mediated via the ERK1/2 pathway. (A) Endothelial network formation and (B)
proliferation in HUVECs treated with V CM or P CM in the absence/presence of inhibitors of ERK1/2 (PD98059), mTOR (rapamycin) or PI3K
(wortmannin or LY294002). (C) Endothelial network formation and (D) proliferation in HUVECs treated with vehicle or recombinant FGF2 protein
(50 ng/ml) in the absence/presence of rapamycin. Data are expressed as percentage increase over control V CM (where V CM = 100%, not
shown) and presented as mean ± SEM. (* represents statistical significance P < 0.05).
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indicating that FP receptor expression was regulated by
FGF2-FGFR1 interaction via the ERK1/2 pathway.
Next, as PGF2a secretion and FP receptor expression
was increased after P CM treatment, we explored the
direct effect of PGF2a, acting via the FP receptor, on
endothelial cell network formation and proliferation. We
found that addition of 1 μMe x o g e n o u sP G F 2a signifi-
cantly increased endothelial cell network formation (Fig.
5C; P < 0.05). In contrast, incubation of HUVECs with 1
μM PGF2a had no effect on endothelial cell proliferation
(Fig. 5D). To investigate the autocrine/paracrine effect
of PGF2a-FP receptor interaction in P CM-induced
endothelial network formation, we used a short hairpin
RNA (shRNA) adenoviral construct targeted against the
FP receptor (sh478) to knockdown FP receptor expres-
sion in HUVECs. HUVECs were infected with
scrambled adenovirus (scr) or sh478 for 24 hrs. Effi-
ciency of the FP shRNA in ablating receptor expression
was confirmed in the laboratory by quantitative RT-PCR
and Western blot analysis (data not shown). Infection of
HUVECs with sh478, significantly reduced P CM-
induced network formation compared to scrambled con-
trol virus (Fig. 5E, P < 0.05). In contrast, infection of
HUVECs with FP receptor shRNA adenovirus did not
alter P CM-induced endothelial proliferation compared
to HUVECs infected with the control scrambled adeno-
virus (Fig. 5F). Similar data were obtained using a sec-
ond shRNA targeted to a different region of the FP
receptor (sh306; data not shown). To confirm the role
of COX-2 and FP receptor in endothelial cell network
formation, HUVECs were treated with P CM in the
absence or presence of the COX-2 inhibitor (NS398) or
FP receptor antagonist (AL8810) (Fig 5G). Addition of
NS398 or AL8810 significantly inhibited P CM-induced
endothelial cell network formation (Fig 5G, P < 0.05).
Discussion
FGF2 is one of 23 fibroblast growth factor family mem-
bers and signals via one of four receptors, FGFR1, 2, 3
Figure 3 The effect of conditioned medium on ERK1/2 signalling in HUVECs. (A) HUVECs were treated with V CM (V) or P CM (P) for
0,5,10,15,20 and 30 minutes. (B) HUVECs were left untreated (U) or treated with V CM (V) or P CM (P) for 10 mins in the absence/presence of
SU4984, PP2, PD98059 or LY294002. Cell lysates were subjected to immunoblot analysis using antibodies against phosphorylated ERK1/2 (top
panel) and total ERK1/2 (bottom panel). A representative Western blot is displayed with a graph of semi-quantitative analysis of ERK1/2
phosphorylation determined as described in the Methods. (* represents statistical significance P < 0.05) Data are represented as mean ± SEM.
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mRNA in HUVECs incubated with V CM or P CM for 1,2,3,4,6,16 and 24 hrs as determined by quantitative RT-PCR analysis. (C) COX-2 mRNA in
HUVECs incubated with V CM or P CM for 3 hrs in the absence/presence of FGFR1 tyrosine kinase inhibitor SU4984 or ERK1/2 inhibitor PD98059
as determined by quantitative RT-PCR analysis. Data are expressed as fold increase over control V CM (where V CM = 1, not shown). HUVECs
were incubated with V CM or P CM for 0, 3, 6 and 16 hrs and thereafter conditioned medium from HUVECs was collected and used for PGE2 (D)
and PGF2a (E) ELISA analysis as described in the methods. (F) HUVECs were treated with V CM, P CM or P CM and NS398 or indomethacin
(Indometh.) for 6 hrs after which the concentration of PGF2a in the HUVEC medium was determined by ELISA. Data are represented as mean ±
SEM. (* represents statistical significance P < 0.05).
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HUVECs incubated with V CM or P CM for 1,2,3,4,6,16 and 24 hrs as determined by quantitative RT-PCR analysis. (B) FP receptor mRNA in
HUVECs incubated with V CM or P CM for 3 hrs in the absence/presence of FGFR1 tyrosine kinase inhibitor SU4984 or ERK1/2 inhibitor PD98059
as determined by quantitative RT-PCR analysis. HUVECs were incubated with vehicle or exogenous PGF2a (1 μM) and endothelial cell network
formation (C) and proliferation (D) were assessed. HUVECs were infected with scrambled adenovirus (scr) or short hairpin adenovirus targeted
against the FP receptor (sh478) and treated with V CM or P CM. Endothelial network formation (E) and proliferation (F) was determined as
described in the methods. (G) HUVECs were incubated with V CM or P CM in the absence/presence of NS398 or indomethacin and network
formation was assessed. Data are expressed as fold or percentage increase over control V CM (V CM = 1 or 100%, not shown) and represented
as mean ± SEM. (* represents statistical significance P < 0.05).
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endothelial cells [18]. A principal role of secreted FGF2
is to stimulate blood vessel growth although we have
shown previously that it can also act as a potent auto-
crine growth factor to enhance epithelial cell prolifera-
tion [12]. In vitro and animal xenograft studies have
shown that secretion of epithelial FGF2 in endometrial
adenocarcinoma xenografts can enhance tumour growth
by enhancing blood vessel size and width [19]. Further-
more antisense targeting of FGF2 in such model systems
is known to reduce tissue microvascular density as well
as xenograft size [20].
Endothelial cell differentiation and proliferation are
two of the processes required for angiogenesis
[11,21-23]. In the present study we have shown that
conditioned medium from endometrial adenocarcinoma
cells, which stably express the FP receptor to the levels
observed in endometrial adenocarcinomas (FPS cells)
and produce FGF2, promotes endothelial network for-
mation (differentiation) and proliferation. Using a speci-
fic FGFR1 tyrosine kinase inhibitor and FGF2-
immunoneutralised conditioned medium, we showed
that the effects of conditioned medium on endothelial
cell network formation and proliferation were via FGF2-
FGFR1 signalling. We found that although the FGF2-
immunoneutralised treatment inhibited network forma-
tion and proliferation, it was less effective than the
FGFR1 inhibitor SU4984. We believe this difference lies
in the residual FGF2 remaining in the FGF2-immuno-
neutralised CM after neutralisation [12] which could,
albeit to a lesser extent, activate the FGF receptor on
HUVECs.
To explore the signalling pathways activated in
HUVECs by FGF2, following its release from epithelial
cells in response to PGF2a-FP receptor activation, we
used small molecule chemical inhibitors of intracellular
signalling pathways. We found that conditioned medium
from PGF2a-treated Ishikawa FPS cells enhanced
endothelial cell network formation via FGFR1 and
ERK1/2 independently of PI3K and mTOR. This is in
agreement with the observations of Kanda et al. [24],
who demonstrated in murine brain endothelial cells that
FGF2 induced endothelial network formation is not
dependent on activation of the mTOR pathway [24] and
Sulpice et al [25] who showed that, in adrenal cortex
capillary endothelial cells,E R K 1 / 2p h o s p h o r y l a t i o n
induced by recombinant FGF2 is not mediated via the
PI3K pathway [25]. Similarly, Peng et al. showed that
FGF2 treatment can induce mTOR phosphorylation in
HUVECs [26].
In contrast, we found that conditioned medium-
induced endothelial cell proliferation was dependent on
ERK1/2 signalling to mTOR as endothelial cell prolifera-
tion could be inhibited with the ERK1/2 kinase inhibitor
PD98059 and rapamycin, but not the PI3K inhibitors
wortmannin or LY294002. This is in agreement with
previous studies showing that the ERK1/2 inhibitor
PD98059 can inhibit FGF2- induced angiogenesis [27]
and HUVEC proliferation [28]. Our data indicate that
endothelial network formation and proliferation are
regulated by distinct signal transduction pathways which
are integrated by ERK1/2 signalling.
ERK1/2 is known to be a potent regulator of cell
growth, differentiation and development [29]. Once
phosphorylated, ERK1/2 can translocate to the nucleus
and promote gene transcription [29]. The phosphoryla-
tion and activation of ERK1/2 can be modulated via a
multitude of intracellular signal transduction pathways.
Hence, we investigated conditioned medium signalling
to ERK1/2 in HUVECs and found within our experi-
mental paradigm that ERK1/2 was phosphorylated in a
time dependent manner. The fact that ERK1/2 is acti-
vated by P CM and that the ERK1/2 inhibitor abolished
ERK1/2 phosphorylation, as well as endothelial network
formation and proliferation, suggests that ERK1/2 could
act as a major transcriptional regulator in this model
system. This phosphorylation and activation of ERK1/2
was found to be regulated via FGFR1 signalling to c-Src,
since co-treatment of HUVECs with P CM and the
FGFR1 inhibitor SU4984 or cSrc inhibitor PP2 signifi-
cantly inhibited ERK phosphorylation. Furthermore
ERK1/2 phosphorylation was found to be independent
of PI3K and mTOR as neither the PI3K inhibitor
LY294002 nor the mTOR inhibitor rapamycin (data not
shown) inhibited P CM-induced ERK1/2 phosphoryla-
tion. c-Src is a protein tyrosine kinase which co-ordi-
nates a diverse spectrum of receptor-induced signalling
to ERK1/2 via the phosphorylation of signalling inter-
mediates such as Ras and Raf [30]. c-Src has been
s h o w nt ob ei n v o l v e di nF G F - 2i n d u c e da n g i o g e n e s i s
[31] and a recent study has shown that c-Src, Raf and
ERK1/2 are essential for HUVEC lumen formation in
vitro [32]. These data suggest that the FGF2-FGFR1-c-
Src pathway plays a role in the activation of ERK1/2 by
P CM treatment.
Following ERK1/2 activation, mTOR has been shown
to be regulated via the tuberous sclerosis complex 1 and
2 (TSC1/2 also called Hamartin and Tuberin) [33,34].
Phosphorylation of TSC2 by ERK1/2 results in its disso-
ciation from TSC1 and its subsequent degradation via
the ubiquitin pathway. This inactivates the inhibitory
effect of TSC1/2 on the mTOR pathway and allows cel-
lular proliferation to proceed [35].
Over the past decade several reports have highlighted
the importance of COX enzymes and prostaglandins in
regulating vascular function indirectly. This may occur
via the activation of ERK1/2 signalling resulting in
epithelial or stromal cell production of pro-angiogenic
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cells [4,36,37]. This is in agreement with our observa-
tions here whereby FGF2, released by Ishikawa FPS cells
in response to PGF2a, enhanced the expression of COX-
2 in endothelial cells via the FGF2-FGFR1-ERK1/2 path-
way. Similarly, FGF2 has been shown to upregulate
endothelial COX-2 in murine cerebral microvascular
cells leading to an increase in prostaglandin E2 produc-
tion [38].
Prostaglandins have been shown to be secreted by
endothelial cells and to influence directly endothelial
cell function via their receptors on endothelial cells
[39-41]. These studies showed that PGE2 present in the
endothelial environment can enhance endothelial cell
functions [38-41], however in our study we found no
significant elevation in PGE2 biosynthesis in response to
P CM. Instead, we found that endothelial cells secrete
elevated levels of PGF2a following activation by CM
from PGF2a-treated Ishikawa FPSc e l l sa n dt h a tt h i s
PGF2a secretion was regulated via the FGF2-FGFR1-
ERK1/2-mediated induction of COX-2 since the specific
COX-2 inhibitor significantly reduced PGF2a secretion.
In order to determine whether COX-1 contributed
towards the generation of PGF2a, a general COX inhibi-
tor indomethacin was used. Co-treatment of cells with
indomethacin significantly reduced PGF2a secretion to a
level below that observed for the specific COX-2 inhibi-
tor suggesting that basal levels of COX-1 may, to a les-
ser extent, contribute towards the secretion of PGF2a.
T h e s ed a t ai n d i c a t et h a ta l t h o u g hP G E 2 is secreted in
higher quantities than PGF2a by unstimulated HUVECs
[42], under P CM stimulated conditions, prostaglandin
F2a is the predominant COX-2 product. Furthermore,
this suggests that the endothelial signalling pathways
induced by FGF2 are context dependent, i.e. dependent
on the nature of the external stimulus, such as cancer
conditioned medium, from which the FGF2 originates.
We found exogenous prostaglandin F2a was able to sti-
mulate endothelial cell network formation but not pro-
liferation. Interestingly, the effect of exogenous PGF2a
on network formation was less than that observed for P
CM. We believe that the higher levels of FP receptor in
endothelial cells induced by P CM accounts for this dif-
ference. It is likely that the upregulated FP receptor in P
CM treated HUVECs would enable a greater signalling
capacity and ability to form networks compared with
HUVECs treated with exogenous PGF2a alone in the
absence of growth factors, where FP receptor expression
is not induced. Using a specific FP receptor short hair-
p i nR N A( F Ps h R N A )i na na d e n o v i r a ld e l i v e r ys y s t e m
for targeted ablation of endothelial FP receptor, we
found that P CM-induced endothelial network forma-
tion was regulated by the endothelial FP receptor. In
addition, the use of a chemical inhibitor against COX-2
and a specific FP receptor antagonist further confirmed
ar o l ef o re n d o t h e l i a lP G F 2a signalling through the
endothelial FP receptor in the regulation of P CM-
induced endothelial cell network formation.
Conclusions
As summarised in fig. 6, our data show that PGF2a-FP
receptor signalling in endometrial adenocarcinoma cells
produces FGF2, which acts in a paracrine manner on
endothelial FGFR1 to promote endothelial cell differen-
tiation and proliferation via distinct intracellular
mechanisms. We demonstrate a novel mechanism
whereby FGF2 induces the secretion of prostaglandin
F2a to regulate P CM-induced endothelial cell differen-
tiation. This the first study to show, with FP shRNA,
that endothelial FP receptors can mediate endothelial
cell differentiation but not proliferation. We believe that
these findings have relevance for endometrial patholo-
gies, such as endometrial adenocarcinoma, which have
aberrant expression of FP receptor and we propose a
molecular mechanism whereby FP receptor may regulate
vascular function [13,43]. Furthermore our data suggest
that targeted antagonism of epithelial FP receptor sig-
nalling, to reduce the production of growth factors, or
endothelial FP receptor signalling, to prevent differentia-
tion of endothelial cells, could provide an anti-angio-
genic approach to reducing tumour vasculature and
growth.
Methods
Reagents
T h eF G F 2a n t i b o d yr e c o g n i s i n gt h e1 8k D ai s o f o r mo f
FGF2 (sc1360) was purchased from Santa Cruz Biotech-
nology (Autogen-Bioclear, Wiltshire, UK). Arachidonic
acid (AA), PGF2a and indomethacin were purchased
from Sigma Chemical Co. (Dorset, UK). PD98059,
SU4984, LY294002, PP2, NS398, wortmannin and rapa-
mycin were purchased from Calbiochem (Nottingham,
UK). Recombinant FGF2 peptide was purchased from
PeproTechEC Ltd. (London, UK). Anti-phospho-p42/44
ERK and anti-p42/p44 ERK were purchased from Cell
Signalling Technologies/New England Biolabs (Hertford-
shire, UK).
Cell culture
Ishikawa cells stably expressing FP receptor (Ishikawa
FPS cells) were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM, Invitrogen, Paisley, UK) with 10% foe-
tal bovine serum (FBS) and 1% penicillin/streptomycin
as described previously [13]. Human umbilical vein
endothelial cells (HUVECs) ( L o n z a ,W a l k e r s v i l l e ,U S A )
were cultured in Endothelial Basal Medium (EBM-2)
with 2% FBS and growth supplements (VEGF, FGF,
P G D F ,I G F ,E G F ,a s c o r b i cacid, heparin and gentamy-
cin) subsequently referred to as Endothelial Growth
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Page 9 of 13Medium (EGM-2) (Lonza, Walkersville, USA). Under
experimental conditions HUVECs were incubated with
EBM-2 containing 1% fetal bovine serum (FBS) with the
addition of ascorbic acid and gentamycin (EBM1%)
(Lonza, USA). Cell viability in the presence of chemical
compounds used to inhibit specific signal transduction
pathways was assessed using the CellTitre96AQueous
One Solution Proliferation Reagent (Promega, South-
ampton, UK).
Conditioned medium
Conditioned medium (CM) was prepared as described
previously [12]. Briefly, FPS cells were seeded at a den-
sity of 2 × 10
6 cells and allowed to adhere before
serum-starvation for 24 hrs. Thereafter, cells were trea-
ted with 20 mls of DMEM containing 8.4 μMi n d o -
methacin in the presence of 100 nM PGF2a or vehicle
for 24 hrs to create PGF2a conditioned medium (P CM)
or vehicle conditioned medium (V CM). Conditioned
medium from three independent experiments was
pooled, aliquoted and stored at -20°C until required.
FGF2 was immunoneutralised from the PGF2a condi-
tioned medium by overnight incubation with 0.5 μg/ml
FGF2 antibody. The immune complex was removed by
4 hr incubation with 20 μl of a 50% protein A plus G
slurry (Calbiochem). Conditioned medium immunoneu-
tralised with Goat IgG was used as a control. Immuno-
neutralised CM was aliquoted and stored at -20°C until
use. The FGF2 content in the CM before and after
immunoneutralisation was confirmed by ELISA as
described previously [12].
Network assays
Network assays were carried out using 12-well Trans-
well plates (Corning Costar, Cambridge, UK). The upper
chambers were coated with 80 μl of growth factor (GF)-
reduced Matrigel (BD Biosciences, MA, USA) in the
absence/presence of SU4984 (20 μM), PD98059 (50
μM), rapamycin (100 ng/ml), wortmannin (200 nM),
LY294002 (50 μM), NS398 (10 μM) or AL8810 (50 μM)
and incubated at 37°C for 30 mins to allow thin gel for-
mation. HUVECs were plated onto the gel (2.5 × 10
4
cells/well) in EBM 1%. In the lower chamber V CM or
P CM was added. Transwell plates were incubated at
37°C in a 5% CO2 atmosphere for 16 hrs. Subsequently,
cell networks were fixed with 100% ice cold methanol
and stained with haematoxylin. To assess network for-
mation, each well was divided into 5 sections. Hotspots
of each section were photographed, 5 photos per well at
×10 magnification, using an inverted microscope and
camera (Axiovert 200, Carl Zeiss, Germany). The num-
ber of network branches was counted blind. Experi-
ments were repeated at least four times in duplicate.
Fold difference was determined by dividing the value
obtained from P CM treated cells by the value obtained
from V CM treated cells. Data were transformed to per-
centage increase in network formation with V CM =
100% and are presented as mean ± SEM.
Proliferation assay
HUVECs were seeded in 96-well plates at 3000 cells/
well. Following attachment, cell medium was replaced
with EBM1% for 3 hours. Cells were then treated with
CM, diluted 1:1 (v/v) with EBM1%, in the absence/pre-
sence of SU4984, PD98059, rapamycin, wortmannin,
LY294002 or FGF2-immunoneutralised CM. Treatments
were replaced three times during the 96 hr incubation.
Proliferation was determined using the CellTitre96AQu-
eous One Solution Proliferation Reagent (Promega) as
per the manufacturer’s instructions. The experiments
Figure 6 A schematic representation of PGF2a-FP receptor
signalling which differentially regulates endothelial network
formation and proliferation. PGF2a-FP receptor signalling in
epithelial cells promotes the release of FGF2 into culture medium
(conditioned medium). Conditioned medium treatment of HUVECs
promotes the activation of ERK1/2 signalling via the FGF2-FGFR1.
ERK1/2 activates divergent signalling pathways to endothelial
proliferation and network formation. Endothelial proliferation is
activated via mTOR. Endothelial network formation is activated via
the induction of endothelial COX-2 enhancing the biosynthesis and
release of PGF2a. Endothelial PGF2a subsequently acts on
endothelial FP receptors to promote network formation (endothelial
differentiation).
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ence was determined by dividing the absorbance
obtained by P CM treated cells by the absorbance
obtained by V CM treated cells. Data were transformed
to percentage increase in proliferation with V CM =
100% and are presented as mean ± SEM.
Western Blot analysis
HUVECs were seeded at 2 × 10
5 cells per 60 mm dia-
meter dish and left to adhere for 24 hrs before GF-star-
vation overnight. The next day, HUVECs were treated
with P CM or V CM for the time indicated in the figure
legend, rinsed with ice-cold phosphate-buffered saline
and lysed for 20 mins with protein lysis buffer contain-
ing inhibitor cocktail mix as described previously [43].
Protein concentration was determined with a protein
assay (BioRad, Hercules, CA) and approximately 16 μg
of protein was resolved and immunoblotted as pre-
viously described [44]. Immunoblots were blocked in
Odyssey Blocking buffer™ (LI-COR Biosciences, Cam-
bridge, UK) before overnight incubation with primary
phospho-p42/44 and p42/44 antibodies (diluted 1:1000
in Odyssey blocking buffer) at 4°C. The following day,
blots were washed and incubated with the goat anti-
mouse IRDye™ 800 (1:10,000) (Rockland Immunochem-
icals Inc., Gilbertsville, PA, USA) and goat anti-rabbit
Alexafluor 680 (1:5000) (Invitrogen) for 60 minutes at
room temperature. Immunoreactive proteins were
detected and quantified using the Odyssey infrared ima-
ging system (LI-COR Biosciences). ERK1/2 phosphoryla-
tion was calculated by dividing the value obtained from
the phosphorylated ERK1/2 channel (700 nm) by the
value obtained from total ERK1/2 channel (800 nm) and
expressed as fold above vehicle controls. Results are
expressed as mean ± SEM from at least four indepen-
dent experiments.
Taqman quantitative RT-PCR
Taqman RT-PCR was performed as described previously
using sequence specific primers and probes designed to
span an intron [43,45,46]. Briefly, HUVECs were seeded
at 5 × 10
4 cells per well with EBM1% in a 6 well plate.
Following overnight serum starvation, cells were treated
with V CM or P CM, diluted 1:1 (v/v) with EBM 1% in
the absence or presence of SU4984 (20 μM) or PD98059
(50 μM) for the time indicated in the figure legends.
RNA was extracted, reverse transcribed and RT-PCR
performed using the ABI Prism 7900 as described pre-
viously [12]. COX-1, COX-2 and FP mRNA were nor-
malized using ribosomal 18S as an internal control.
Experiments are representative of at least five indepen-
dent experiments. Fold difference was determined by
dividing the value obtained from P CM treated cells by
the value obtained from V CM treated cells and repre-
sented as mean ± SEM.
PGF2a/PGE2 ELISA
HUVECs were seeded at a density of 5 × 10
4 cells per
35 mm diameter dish and serum starved overnight.
Thereafter cells were treated with V CM or P CM
diluted 1:1 (v/v) with EBM 1% containing 3 μg/ml ara-
chidonic acid for the time indicated in the figure legend.
After treatment CM was collected and stored at -20°C
until required. PGF2a and PGE2 secretions in the culture
m e d i aw e r ea s s a y e db yE L I S Aas described previously
[47,48]. When using chemical inhibitors, cells were pre-
incubated with EBM1% and NS398 (10 μM) or indo-
methacin (8.4 μM) for 30 minutes and subsequently,
cells were treated with V CM or P CM in the absence
or presence of inhibitors with the addition of 3 μg/ml
arachidonic acid for 6 hrs. Experiments were repeated
three times. The data are presented as mean ± SEM.
Short hairpin DNA constructs and preparation of
adenoviral stocks
To generate FP receptor knockdown vectors, oligonu-
cleotides encoding short hairpin transcripts were
annealed and individually cloned into the adenovirus
shuttle vector pDC316. The start codon of the FP recep-
tor (NM_000959) was used as a reference and labelled
as basepair 1. Thus the target sequences corresponded
t o4 7 8b pd o w n s t r e a ma n di n c l u d e das c r a m b l e d( s c r )
negative control: Sh478: 5’-GTGGCCTGGTAAT-
C A C T G A ;s c r :5 ’-TTACTCGACGCATGTGCTT. High
titre stocks (<10e10 viral plaque forming units/ml, pfu/
ml) were prepared using the AdMax system (Microbix
Biosystems Inc., Toronto, Ontario, Canada). Briefly, an
adenovirus genomic plasmid (pBHGLoxdeltaE1,3Cre)
was cotransfected with the shuttle vector into HEK293
cells. After 10 days, plaques were purified and seeded
into a T75 flask of HEK293 to generate the first seed.
When HEK293 cells showed a cytopathic response; virus
was released from the cells by three cycles of freeze
thawing. This starter culture was used to produce large
bulk preparations of adenovirus. Viral particles were
purified using a Vivascience AdenoPack column (Gen-
eron House, Eton Wick, UK), buffer exchanged into 8
volumes of 2.5% glycerol, 20 mM Tris-HCl (pH 8) and
then concentrated. The viral titre was determined using
a modified Adeno-X rapid titre kit (Clontech-Takara Bio
Europe, Saint-Germain-en-Laye, France) with 1:1000
rabbit anti-adenovirus Serotype 5 hexon antisera (Lab-
frontier, Seoul, Korea).
To ablate FP receptor expression, HUVECs were
seeded at a density of 3 × 10
5 cells/25 cm
2 in EGM-2
and incubated with 100 viruses (either scr or sh478) per
cell (MOI) for 24 hrs at 37°C in a 5% CO2 atmosphere.
The next day, the viral infected cells were washed, tryp-
sinised, counted and used in the network formation and
proliferation assays.
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Statistical significance was assessed on untransformed
data with one-way ANOVA and Dunnett’s post hoc test
using Prism 5.0 (Graph Pad, San Diego, CA). A p-value
of less than 0.05 (P < 0.05) was considered to be statisti-
cally significant.
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